StreetInsider.com News Articles

Leerink Partners Reiterates Outperform Rating on Vericel Corporation (VCEL) following conference

Tue, 10 Mar 2026 15:55:44 -0400

Leerink Partners analyst Mike Kratky reiterated an Outperform rating and $46.00 price target on Vericel Corporation (NASDAQ: VCEL)

The analyst commented, "Bottom Line: We remain positive on VCEL and the company's growth outlook for FY26 following management’s commentary at the Leerink Partners Global Healthcare Conference. We spoke with CFO Joe Mara and VP of Finance & Investor Relations Eric Burns about the key drivers of management’s outlook in FY26. Following the strong momentum seen in MACI KPIs and underlying growth in 4Q, management remains confident that these trends will continue in 1Q and beyond, particularly following the completion of its sales

Form 4 Vericel Corp For: Mar 02 Filed by: Flynn Sean C.

Wed, 04 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260304/26110979.html

Form 4 Vericel Corp For: Mar 02 Filed by: Flynn Sean C.

Wed, 04 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260304/26110979.html

Form 4 Vericel Corp For: Mar 02 Filed by: Halpin Michael

Wed, 04 Mar 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260304/26110961.html

Form 4 Vericel Corp For: Mar 02 Filed by: Halpin Michael

Wed, 04 Mar 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260304/26110961.html

Vericel receives FDA approval for MACI manufacturing facility

Wed, 04 Mar 2026 08:00:24 -0400

Vericel Corporation (NASDAQ: VCEL) announced that the U.S. Food and Drug Administration has approved commercial manufacturing of MACI at its cell therapy facility in Burlington, Massachusetts. MACI is an autologous cultured chondrocyte product used for cartilage repair.

The approval allows Vericel to begin commercial production of MACI at the new facility in the second quarter of 2026. The company stated the facility will increase manufacturing capacity and enable potential commercialization of MACI outside the United States.

"This FDA approval reflects a major achievement for Vericel and underscores the Company's operational and scientific expertise in complex cell therapy manufacturing," said Nick Colangelo, President

Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility

Wed, 04 Mar 2026 08:00:00 -0400

Company Achieves Significant Regulatory and Operational Milestone

Substantially Increases Manufacturing Capacity to Support Long-Term Growth

Enables Potential MACI Commercialization Outside of the U.S.

CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for MACI^® (autologous cultured chondrocytes on porcine collagen membrane) commercial manufacturing at its state-of-the-art cell therapy manufacturing facility in Burlington, Massachusetts. The approval enables Vericel to begin commercial production of MACI

Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility

Wed, 04 Mar 2026 08:00:00 -0400

Company Achieves Significant Regulatory and Operational Milestone

Substantially Increases Manufacturing Capacity to Support Long-Term Growth

Enables Potential MACI Commercialization Outside of the U.S.

Vericel to Present at Multiple Upcoming Investor Conferences

Tue, 03 Mar 2026 08:30:00 -0400

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences:

TD Cowen 46^th Annual Healthcare Conference on Wednesday, March 4^th, 2026
Leerink Partners 2026 Global Healthcare Conference on Tuesday, March 10^th, 2026

A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leading provider

Vericel to Present at Multiple Upcoming Investor Conferences

Tue, 03 Mar 2026 08:30:00 -0400

TD Cowen 46^th Annual Healthcare Conference on Wednesday, March 4^th, 2026
Leerink Partners 2026 Global Healthcare Conference on Tuesday, March 10^th, 2026

A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leading provider

Form 144 Vericel Corp Filed by: Flynn Sean C.

Mon, 02 Mar 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260302/26093332.html

Form 144 Vericel Corp Filed by: Flynn Sean C.

Mon, 02 Mar 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260302/26093332.html

Form 144 Vericel Corp Filed by: Halpin Michael

Mon, 02 Mar 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260302/26092512.html

Form 144 Vericel Corp Filed by: Halpin Michael

Mon, 02 Mar 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260302/26092512.html

Vericel Corporation (VCEL) PT Raised to $64 at H.C. Wainwright

Mon, 02 Mar 2026 06:58:45 -0400

(Updated - March 2, 2026 6:58 AM EST)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Vericel Corporation (NASDAQ: VCEL) to $64.00 (from $60.00) while maintaining a Buy rating.

The analyst commented: "On February 26, Vericel Corporation announced 4Q25 financial results and held a conference call. The company reported FY2025 MACI revenue growth of 21% YoY or $239.5M. For 2026, management provided an annual revenue guidance range of $280M-$286M—implying an ~18% growth rate at midpoint. We believe this is conservative given that the company noted 1Q26 total revenue growth is already trending towards 20%. Strategic growth levers for 2026 include

Vericel Corporation (VCEL) PT Raised to $64 at H.C. Wainwright

Mon, 02 Mar 2026 06:58:45 -0400

(Updated - March 2, 2026 6:58 AM EST)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Vericel Corporation (NASDAQ: VCEL) to $64.00 (from $60.00) while maintaining a Buy rating.

Vericel Corporation (VCEL) PT Raised to $48 at Truist Securities

Fri, 27 Feb 2026 07:07:39 -0400

Truist Securities analyst Richard Newitter raised the price target on Vericel Corporation (NASDAQ: VCEL) to $48.00 (from $45.00) while maintaining a Buy rating.

Form 4 Vericel Corp For: Feb 24 Filed by: Flynn Sean C.